These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11584997)

  • 1. Current pharmacotherapy for hepatitis B infection.
    Galan MV; Boyce D; Gordon SC
    Expert Opin Pharmacother; 2001 Aug; 2(8):1289-98. PubMed ID: 11584997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of viral hepatitis B.
    Pramoolsinsup C
    J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S125-45. PubMed ID: 12000599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical potential of emerging new agents in hepatitis B.
    Farrell GC
    Drugs; 2000 Oct; 60(4):701-10. PubMed ID: 11085196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic management of hepatitis B-related cirrhosis.
    Merle P; Trepo C
    J Viral Hepat; 2001 Nov; 8(6):391-9. PubMed ID: 11703569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional interferon alpha for lamivudine resistant hepatitis B infection after liver transplantation: a preliminary report.
    Seehofer D; Rayes N; Berg T; Neuhaus R; Hopf U; Müller AR; Bechstein WO; Neuhaus P
    Transplantation; 2000 Apr; 69(8):1739-42. PubMed ID: 10836394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B.
    Rivkin A
    Drugs Today (Barc); 2007 Apr; 43(4):201-20. PubMed ID: 17460784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients.
    Ingiliz P; Valantin MA; Thibault V; Duvivier C; Dominguez S; Katlama C; Poynard T; Benhamou Y
    Antivir Ther; 2008; 13(7):895-900. PubMed ID: 19043923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New developments in therapy of chronic hepatitis B. When are nucleoside analogs indicated?].
    Petry W; Erhardt A; Heintges T; Häussinger D
    Z Gastroenterol; 2000 Jan; 38(1):77-87. PubMed ID: 10689749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral hepatitis B.
    Lai CL; Ratziu V; Yuen MF; Poynard T
    Lancet; 2003 Dec; 362(9401):2089-94. PubMed ID: 14697813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
    Peters MG; Hann Hw Hw; Martin P; Heathcote EJ; Buggisch P; Rubin R; Bourliere M; Kowdley K; Trepo C; Gray Df Df; Sullivan M; Kleber K; Ebrahimi R; Xiong S; Brosgart CL
    Gastroenterology; 2004 Jan; 126(1):91-101. PubMed ID: 14699491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B.
    Han SH
    Drugs; 2006; 66(14):1831-51. PubMed ID: 17040114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of hepatitis B virus infection].
    Trautwein C
    Praxis (Bern 1994); 2006 Sep; 95(36):1389-97. PubMed ID: 16989182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of patients with chronic hepatitis B.
    Liaw YF
    J Gastroenterol Hepatol; 2002 Apr; 17(4):406-8. PubMed ID: 11982720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early detection of hepatitis B drug resistance: implications for patient management.
    Sablon E; Shapiro F; Zoulim F
    Expert Rev Mol Diagn; 2003 Sep; 3(5):535-47. PubMed ID: 14510175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.
    Delaney WE; Locarnini S; Shaw T
    Antivir Chem Chemother; 2001 Jan; 12(1):1-35. PubMed ID: 11437320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
    Kanwal F; Gralnek IM; Martin P; Dulai GS; Farid M; Spiegel BM
    Ann Intern Med; 2005 May; 142(10):821-31. PubMed ID: 15897532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?
    Buster EH; Janssen HL
    Neth J Med; 2006 Jun; 64(6):175-85. PubMed ID: 16788215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B.
    Liu Y; Wang C; Zhong Y; Chen L; Li X; Ji D; Wang H; Xin S; Zoulim F; Xu D
    Antivir Ther; 2010; 15(8):1185-90. PubMed ID: 21149926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.